Newron Pharmaceuticals S.p.A. (NWPHF) Discusses FDA Clinical Hold and Safety Concerns in ENIGMA-TRS Program for Treatment-Resistant Schizophrenia Transcript#Newron #Pharmaceuticals #S.p.A #NWPHF #Discusses #FDA #Clinical #Hold #Safety #Concerns #ENIGMATRS #Program #TreatmentResistant #Schizophrenia #Transcript
Real‑time stock data, professional analysis, and smart portfolio tools. One platform for all your investing needs.
